news

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

Securities Times reporter Chen Cheng

On the evening of August 13, Lukang Pharmaceutical (600789) announced that its holding subsidiary Shandong Lukang Pharmaceutical Group Saite Co., Ltd. (hereinafter referred to as "Saite Company") recently received the "Drug Registration Certificate" for Adenosylcobalamin Capsules issued by the State Food and Drug Administration. Since the development of this drug, Saite Company has invested a total of approximately RMB 2.7605 million in research and development (unaudited).

According to the information, adenosylcobalamin capsules are mainly used for the prevention and treatment of vitamin B12 deficiency, megaloblastic anemia, and neurological diseases related to pernicious anemia.

Adenosylcobalamin is a congener of cyanocobalt vitamin B12. It is an important coenzyme for the synthesis of nucleotides in cells. It participates in methyl conversion and folic acid metabolism in the body, and promotes the reduction of methylfolate to tetrahydrofolate. It also participates in the tricarboxylic acid cycle and is very important for the formation of lipoproteins in nerve myelin. It can keep sulfhydryl enzymes in an active state, thereby participating in a wide range of protein and fat metabolism. This product can promote the development and maturation of red blood cells, which is a necessary factor for the complete formation of nerve sheath spinal cord fibers and maintaining the function of epithelial cells in the digestive system.

Industry data shows that there are currently 5 production approvals for adenosine cobalamin capsules in China, and 5 approvals from 5 companies are deemed to have passed the generic drug quality and efficacy consistency evaluation approval.

Yaozhi data shows that the total sales of adenosylcobalamin tablets with the same active ingredient in hospitals across the country from 2021 to 2023 will be approximately RMB 320 million, RMB 495 million, and RMB 630 million, respectively.

Lukang Pharmaceutical said that the "Drug Registration Certificate" for Adenosylcobalamin Capsules indicated that the drug was deemed to have passed the quality and efficacy consistency evaluation of generic drugs. The approval of this registration certificate further enriched Saite's product pipeline and enhanced the market competitiveness of its products.

Lu'an Pharmaceutical is expected to disclose its 2024 semi-annual report on August 22. According to previous performance forecasts, Lu'an Pharmaceutical expects to achieve a net profit attributable to the parent company of 291 million yuan to 311 million yuan in the first half of 2024, a year-on-year increase of 122% to 137%; it is expected to achieve a net profit attributable to the parent company after deducting non-recurring items of 88.16 million yuan to 99.66 million yuan, a year-on-year increase of 12% to 27%.